Resolution of Choroidal Neovascularization Secondary to Punctate Inner Choroidopathy (PIC) with Intravitreal Anti-VEGF Agents: A Case Series

Mangat, Simran Singh; Ramasamy, Balasubramanian; Prasad, Somdutt; Walters, Gavin; Mohammed, Moin; McKibbin, Martin

doi:10.3109/08820538.2010.541322

Cited by 10 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our rate of female patients was a little lower than in larger series of patients affected by PIC without complicating CNV where female rates of up to 93% were reported [9,12]. However, in case series recording selectively PIC-related CNV the female portion varied between 50 and 92% [2,22,[25][26][27]. All of our patients showed the classic type of neovascular membranes on FFA imaging.…”

Section: Discussioncontrasting

confidence: 70%

“…However, some case reports [20][21][22][23][24] and small case series [2,26,27] have been published on intravitreal anti-VEGF therapy for this condition in the past. There are also larger studies about intravitreal antiangiogenic substances in inflammatory ocular [27] and CNV in young patients (\50 years of age) from causes other than AMD [17,25].…”

Section: Discussionmentioning

confidence: 99%

“…However, due to the rarity of PIC-related CNV no evidence-based treatment protocol exists [1,13]. So far only single case reports [20][21][22][23][24] or small patient series [2,25,27] have been published on intravitreal treatment of CNV secondary to PIC. Here, we describe morphologic characteristics of PIC-associated CNV and visual outcome of intravitreal antiangiogenic treatment in a monocentric, retrospective analysis with a mean follow-up of 15 months after the last injection.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Several recent studies have reported that anti-VEGF agents, bevacizumab and ranibizumab were efficacious in treating CNV secondary to PIC [8, 28, 29]. Particularly, a case series study found that intravitreal anti-VEGF resolved CNV secondary to PIC over a 3–28 months follow-up period [10]. …”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Peng

Zhang

et al. 2017

BMC Ophthalmol

View full text Add to dashboard Cite

BackgroundTo evaluate the efficacy and safety of intravitreal conbercept (KH902) as the primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy.MethodsThis study was a retrospective, consecutive, observational case series. We reviewed medical records of 16 eyes (16 patients) with naive subfoveal or juxtafoveal choroidal neovascularization secondary to punctuate inner choroidopathy that were treated with intravitreal conbercept injections. All patients completed at least six months of follow-up. Best-corrected visual acuity (BCVA) was measured, and anatomical features were assessed with fluorescein angiography, indocyanine green angiography, and optical coherence tomography.ResultsAt the month-6 follow-up visit, best-corrected visual acuity improved from 0.70 ± 0.36 (with approximate Snellen equivalent of 20/100) to 0.44 ± 0.25 (20/50 in Snellen) logarithm of the minimum angle of resolution (logMAR) (P = 0.003). Mean improvement of vision was 2.6 lines, with 50% treated eyes (8 eyes of 16) showing an improvement of ≥3 lines and 62.5% (10 eyes of 16), obtaining an improvement of ≥2 lines; all 16 eyes had stable or improved vision. Mean central retinal thickness decreased from 294.94 ± 102.68 μm to 206.56 ± 61.71 μm (P = 0.005). Fifteen eyes (93.75%) showed absence of CNV leakage at the end of the study period. No conbercrept-related systemic or ocular adverse events were observed.ConclusionIntravitreal injection of conbercept significantly improved visual and anatomical outcomes in choroidal neovascularization secondary to punctate inner choroidopathy over a 6-month follow-up period.Trial registration ISRCTN85678307, retrospectively registered on May 11, 2017.

show abstract

“…The management of CNV due to PIC has not been conclusively determined, so a variety of treatment options have been described: submacular surgery [6], laser photocoagulation, photodynamic therapy [4], immunosuppressants [7], intravitreal and systemic corticoids [8, 9] and intravitreal anti-VEGF agents [10, 11, 12]. …”

Section: Introductionmentioning

confidence: 99%

Punctate Inner Choroidopathy: A Clinical Case Report

Campos

Beselga

et al. 2013

Case Rep Ophthalmol

View full text Add to dashboard Cite

Purpose: To report an uncommon case of a 29-year-old Caucasian male diagnosed with unilateral choroidal neovascularization (CNV) secondary to punctate inner choroidopathy leading to visual impairment. Methods: This is a retrospective and descriptive case report based on data from clinical records, patient observation and analysis of ancillary diagnostic tests. Results: A 29-year-old Caucasian male presented to our emergency department with complaints of decreased central vision in his left eye (LE), detected a few hours before. Best-corrected visual acuity (BCVA) in the LE was counting fingers at 50 cm and BCVA in the right eye was 20/20. Fundoscopy of the LE evidenced multiple round and yellowish lesions in the macula and nasal to the optic nerve, without intraocular inflammation signs. Optical coherence tomography showed increased retinal thickness with detachment of the neuroepithelium and a slight retinal pigment epithelium detachment. Fluorescein angiography revealed hyperfluorescent lesions with blurred borders in the macula. An intravitreal injection of bevacizumab (1.25 mg/0.05 ml) was administered in the LE, which resulted in anatomic and visual improvement. Conclusion: We present a rare case of unilateral CNV secondary to punctate inner choroidopathy in a young, myopic male.

show abstract

Resolution of Choroidal Neovascularization Secondary to Punctate Inner Choroidopathy (PIC) with Intravitreal Anti-VEGF Agents: A Case Series

Abstract: Case series of four patients with CNVM secondary to PIC treated solely with anti VEGF in three cases and in combination with PDT in the other. This series reveals long term follow up (3 months to 28 months) which is currently not described in the literature.

Cited by 10 publications

References 3 publications

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Punctate Inner Choroidopathy: A Clinical Case Report

Contact Info

Product

Resources

About